RT Journal Article
T1 DREIMT: a drug repositioning database and prioritization tool for immunomodulation.
A1 Troulé, Kevin
A1 López-Fernández, Hugo
A1 García-Martín, Santiago
A1 Reboiro-Jato, Miguel
A1 Carretero-Puche, Carlos
A1 Martorell-Marugán, Jordi
A1 Martín-Serrano, Guillermo
A1 Carmona-Sáez, Pedro
A1 Glez-Peña, Daniel
A1 Al-Shahrour, Fátima
A1 Gómez-López, Gonzalo
AB Drug immunomodulation modifies the response of the immune system and can be therapeutically exploited in pathologies such as cancer and autoimmune diseases. DREIMT is a new hypothesis-generation web tool, which performs drug prioritization analysis for immunomodulation. DREIMT provides significant immunomodulatory drugs targeting up to 70 immune cells subtypes through a curated database that integrates 4960 drug profiles and ∼2600 immune gene expression signatures. The tool also suggests potential immunomodulatory drugs targeting user-supplied gene expression signatures. Final output includes drug-signature association scores, FDRs and downloadable plots and results tables. http://www.dreimt.org. Supplementary data are available at Bioinformatics online.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/16121
UL http://hdl.handle.net/10668/16121
LA en
DS RISalud
RD Apr 8, 2025